STOCK TITAN

Regenerx Biopharmaceuticals - RGRX STOCK NEWS

Welcome to our dedicated news page for Regenerx Biopharmaceuticals (Ticker: RGRX), a resource for investors and traders seeking the latest updates and insights on Regenerx Biopharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Regenerx Biopharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Regenerx Biopharmaceuticals's position in the market.

Rhea-AI Summary
RegeneRx Biopharmaceuticals, Inc. has executed a 1-for-100 reverse stock split and filed Form 15 to suspend and terminate its obligations to file reports with the SEC. Stockholders will receive information from the transfer agent regarding exchange of pre-split stock certificates for post-split certificates and issuance of cash for fractional shares. Future updates will be posted on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
RegeneRx Biopharmaceuticals announces that 48.5% of outstanding stockholders have voted in favor of the proposed reverse stock split. The company is continuing to solicit consents from stockholders to proceed with the planned reverse stock split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Regenerx Biopharmaceuticals

OTC:RGRX

RGRX Rankings

RGRX Stock Data

78.14k
806.79k
44.14%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Rockville

About RGRX

regenerx is a publicly traded, clinical-stage, biopharmaceutical company focused on tissue protection, repair and regeneration. regenerx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. regenerx’s management team is focused on moving three distinct tβ4-based drug candidates through the clinic: rgn-137, rgn-259 and rgn-352. regenerx also holds over 75 issued patents or patent applications worldwide in order to enable and protect multiple indications and applications for its product candidates. currently, regenerx has active partnerships in three major territories: the u.s. and canada, china, and pan asia. our partners have been moving forward and making significant progress in each territory with rgn-259, our ophthalmic drug candidate, and are preparing to initiate their clinical trials programs. in each case, the cost of development is being borne by our partners with no financial ob